ANALYSIS: Keeping a watching brief on the Chinese economy is prudent.
ANALYSIS: Introducing 10 bills to Parliament – which still have to be drafted – will take time.
ANALYSIS: NBR Listers’ pharma company cleared a major FDA hurdle last week but winning the US is far from assured.
ANALYSIS: A new government does not meaningfully change the prevailing fundamentals for most companies.
ANALYSIS: A recommendation that a new independent regulator be established shouldn't fall to the bottom of the new government's legislative priorities.
ANALYSIS: As a dispute over potential liability for bursting pipes in Australia escalates, there are still big holes in each side’s arguments.
ANALYSIS: The Greens scored their second-best result ever but are now out of government.
ANALYSIS: Labour faces the task of rebuilding, while National has to govern.
ANALYSIS: The recent result season presented a large number of ‘one-off losses’. What is happening and what does it mean?
ANALYSIS: Corporates backed a Yes vote with millions of dollars in donations, but their support may have backfired.
